Licensing
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3
CTVA
FY2025 Q4
개선
Corteva, Inc. 실적 발표
Buzzberg 분석
Bayer resolution accelerates royalty neutrality to 2026
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
Buzzberg 분석 Bayer resolution accelerates royalty neutrality to 2026 Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company. 전체 분석 보기분석 접기
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
- Bayer settlement provides freedom to operate, accelerating corn licensing to 2027 and enabling US cotton licensing, with ~$1B EBITDA upside over 10 years.
- 2026 guidance: EBITDA midpoint $4.1B, EPS $3.45-$3.70, with expectations of 60% of sales and 85% of EBITDA in H1.
- Crop protection expects modest market growth in 2026 with volume growth in durables, but faces price pressure in Latin America and Asia Pacific.
매출$3.91B보고값
주당순이익(EPS)$0.22보고값
매출총이익률42.35%보고값
영업이익률6.19%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Licensing
Bayer agreement to generate ~$1B EBITDA upside over 10 years
Licensing
Corn licensing accelerated to 2027, five years earlier
핵심 내용 3개 더 보기
Innovation
Third-gen above-ground trait platform accelerated by two years
Demand
Crop protection market expected to grow modestly in 2026
Innovation
Gene-edited fungal disease resistant corn near commercialization
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $3.91B | 보고값 |
| 주당순이익(EPS) | $0.22 | 보고값 |
| 매출총이익률 | 42.35% | 보고값 |
| 영업이익률 | 6.19% | 보고값 |
| 잉여현금흐름 | $4.153B | 보고값 |
| 자본지출 | $0.222B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 영업이익률 | FY2026 | 22% | 22% | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in 2026 guidance, highlighted record performance, and emphasized accelerated opportunities from the Bayer resolution.
투자 및 생산능력
Management did not provide specific capital expenditure guidance, but mentioned ongoing asset and sourcing optimization in crop protection and investments in innovation, R&D at just over 8% of sales, and separation-related IT system separation costs.
아래에 언급된 기업 1개 모두 표시
기업발표 이후 수익률
파트너
파트너
Chuck Magro
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years. — Opens new revenue streams for Corteva and potentially increases competitive pressure on Bayer's seed businesses.
근거
“We recently reached a comprehensive resolution with Bayer related to our seed, Freedom to Operate.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years.
근거
“This resolution also facilitates the introduction of our third gen above ground trade platform in North America corn, which will be available for branded sales and licensing by the end of the decade.”
The 2026 tariff impact is $80M, mostly on crop protection from China-sourced active ingredients entering the US.
근거
“The estimate that we've got on the crop protection primarily is where the tariffs all are is encompassing everything we've got for the entire business... almost all of it is CP and almost all of it is China actives coming in to the United…”
Corteva expects to reach royalty neutrality in 2026, two years ahead of schedule, due to the Bayer settlement and licensing progress.
근거
“As a result of this resolution and the progress we've been making across the broader outlicensing spectrum, we now expect to achieve royalty neutrality in 2026, which is two years ahead of our most recent expectations.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 1개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.